BioSpace News Archive

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Tammy Sarnelli as Global Head of Regulatory Affairs.

ADA Leads 20 National Patient Advocate Groups Urging USPS Delivery Improvements

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has been awarded a Group Purchasing Agreement with Premier Inc. Effective August 2020, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in com

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has acquired Acessa Health Inc., a privately-held innovator in minimally invasive treatment for fibroids, for approximately $80 million in cash plus contingent payments based on future revenue growth.

Repatha (Evolocumab) Late-Breaking Data Showcase First Phase 3 Study of a PCSK9 Inhibitor in Pediatric Heterozygous Familial Hypercholesterolemia New Data Highlight Gaps in Treating High LDL-C to Clinical Treatment Guidelines in a Large Cohort of European, High-Risk CVD Patients

TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that in connection with the appointment of Shameze Rampertab as the Company’s Executive Vice President and Chief Financial Officer effective August 24, 2020,

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss its financial and operational highlights for the fourth quarter and full-year ended June 30, 2020 (FY2020).

Today Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) is responding to news reports detailing that a federal grand jury in Philadelphia, Pennsylvania has returned a criminal indictment charging Teva USA with three counts of antitrust violations under the Sherman Act.

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a business update including the extension of the patent for TYMLOS® as well as the completion of enrollment for its Phase 3 study, which is assessing the safety and efficacy of abaloparatide-SC in men with osteoporosis.

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at upcoming investor conferences in September,